Overall verdict
Sell
2.9/10
1-year performance
-36.05%
Score breakdown
Down 36.1% over 1 year, 22% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Shareholder return 0.0/10.
Jiangsu CoWin Biotech Co., Ltd. engages in the research, development, sales, testing, and technology services of biological reagents in China. The company offers RT-PCR, PCR, multiplex PCR, and qPCR ; collection, such as cfDNA, fecal DNA, saliva DNA, and urine DNA storage tube, as well as other collection products ; cfDNA, genomic DNA, FFPE DNA extraction, and plasmid kit ; molecular raw materials ;
quantitative analysis, RNA sequencing, adapter, purification magbeads, DNA sequencing, and single cells sequencing products ; molecular cloning, such as cloning reagents ; nucleic acid residue and contamination screening reagent ; and other products. It also provides gene synthesis, gene fragment, and codon optimization services. The company's products and services are used in infectious disease, eugenics and good parenting, and oncology applications. The company was founded in 2007 and is headquartered in Taizhou, China.
Sector
Health Care
Industry
Biotechnology
Primary listing
Sse
China
CEO
Chun Xiang Wang
Founded
2007
Employees
769
Revenue / employee
251 588 CNY
Next earnings
April 23, 2027 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
33.67 CNY
52-week low
14.42 CNY
1-year performance
-36.05%
Declining
Year-to-date performance
-21.96%
Declining
Drawdown
-44.37%
Major drawdown
Position in the 52-week range
22% of range
Gross margin 48.7%, the company loses 35.4% of its revenue, ROIC -6.0%, ROE -6.1%.
Net margin
-35.37%
Negative
Sector -208.32%|S&P 13.40%
Gross margin
48.75%
Exceptional
Return on equity (ROE)
-6.09%
Negative
Sector -57.88%|S&P 17.06%
Return on invested capital (ROIC)
-5.99%
Negative
Free cash flow margin (FCF)
-4.51%
Negative
Margin stability
58.8 pts
Very uneven
Growth
10.0/10Revenue up 24.1% over 1 year, -3.7% a year over 5.
Revenue (trailing 12 months)
242M CNY
Revenue growth (1y)
24.06%
Hyper-growth
Revenue growth (3y)
-62.83%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
1.1/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.8x|S&P 23.6x
Forward P/E (adjusted)
14.1x
Expensive
EV / EBITDA
—
N/A (loss)
Sector 15.0x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Market cap
2.1Md CNY
Financial strength
5.8/10Cash covers 1851.4% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-53.69%
Net cash
Cash
776M CNY
Cash / market cap
37.00%
Very solid
Cash / total debt
1851.41%
Net cash
Interest coverage
-63.9x
Stretched
Net debt
-734M CNY
Equity
1.4Md CNY
Closed daily candles, 2 years
Last close on November 11, 2026: 18.89 CNY
- MM2018.58
- MM5020.15
- MM20020.53
- RSI 1449.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.03%
200-day average slope, 3 months
-9.85%
50-day average slope, 1 month
-0.58%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
3.09 % per day
Volatility change
-3.23%
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR | 5.6 | N/A | 284M USD | Not meaningful (loss) | — | — | -135.7 % | 0.8x | -55.0 % | -21.3 % | ||
| 2 | FYB | 4.8 | 3.2 | 290M USD | Not meaningful (loss) | -41.0 % | -36.2 % | -6.2 % | -4.2x | -2.2 % | -30.3 % | ||
| 3 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 4 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 5 | 688426 | 2.9 | 3.2 | 314M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -36.1 % | ||
| 6 | SABS | 2.9 | 0.9 | 280M USD | Not meaningful (loss) | -6088.9 % | -100.0 % | -34.5 % | 1.2x | -21.0 % | -1.3 % | ||
| 7 | LCTX | 2.7 | 1.5 | 281M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | 1.9x | -8.7 % | -43.3 % | ||
| 8 | A174900 | 2.4 | 2.6 | 298M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.0 % | -10.7 % | ||
| 9 | CRNA | 1.8 | 0.4 | 298M USD | Not meaningful (loss) | — | — | -25.6 % | 8.3x | -1.8 % | 900.5 % |
